GlassScriptPhysician profile
Hamid Kamran
NPI 1609890714
$6,097.01
in general payments reported to CMS, 2019-2025
37 companies · $986 in 2025
The $986 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $504 · 2021: $782 · 2022: $1,009 · 2023: $1,088 · 2024: $1,198 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248 · Education: $24.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.63 |
| Education | $24.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,499.09 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $535.18 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.13 | 2020-2025 | Xifaxan, Trulance |
| Celgene Corporation | $449.46 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $404.76 | 2019-2024 | |
| Janssen Biotech, INC. | $320.74 | 2022-2025 | Stelara, Tremfya, Simponi |
| Braintree Laboratories, INC. | $285.11 | 2019-2023 | Suflave |
| Merck Sharp & Dohme LLC | $202.43 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $138.00 | 2024-2025 | Voquezna |
| Pfizer INC. | $134.89 | 2019-2025 | |
| Ardelyx, INC. | $127.65 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $112.97 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $109.14 | 2023-2024 | Dupixent |
| Echosens North America, INC. | $108.58 | 2022 | |
| Gilead Sciences, INC. | $102.60 | 2019-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $100.90 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $89.31 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $80.80 | 2020-2023 | Rebyota |
| Madrigal Pharmaceuticals | $73.49 | 2025 | Rezdiffra |
| Qol Medical, LLC | $66.34 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $65.60 | 2020-2024 | Ocaliva |
| Shionogi INC | $65.40 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $57.39 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $56.55 | 2021-2023 | Talicia |
| Allergan, INC. | $56.34 | 2019 | |
| Celltrion USA INC. | $53.41 | 2024-2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $49.24 | 2019-2020 | |
| Alfasigma USA, INC. | $40.84 | 2020-2022 | |
| Vivus LLC | $31.65 | 2021-2024 | Qsymia |
| Rigel Pharmaceuticals, INC. | $27.87 | 2023 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $24.88 | 2025 | Omvoh |
| W. L. Gore & Associates, INC. | $24.05 | 2023 | Gore Cardioform Septal Occluder |
| Novo Nordisk INC | $23.65 | 2025 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $18.93 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.42 | 2019 | |
| Evoke Pharma, INC. | $15.41 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $10.81 | 2024 | Rapide Balloons |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Kamran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.